50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
What’s the Obsession Over Inflation? (Ad)pixel
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
What’s the Obsession Over Inflation? (Ad)pixel
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
What’s the Obsession Over Inflation? (Ad)pixel
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
What’s the Obsession Over Inflation? (Ad)pixel
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
What’s the Obsession Over Inflation? (Ad)pixel
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
What’s the Obsession Over Inflation? (Ad)pixel
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
What’s the Obsession Over Inflation? (Ad)pixel
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
What’s the Obsession Over Inflation? (Ad)pixel
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
NASDAQ:GILD

Gilead Sciences - GILD Earnings Date, Estimates & Call Transcripts

$62.34
-0.52 (-0.83%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$62.17
$62.94
50-Day Range
$59.54
$68.01
52-Week Range
$57.17
$74.12
Volume
6.12 million shs
Average Volume
8.73 million shs
Market Capitalization
$78.13 billion
P/E Ratio
19.01
Dividend Yield
4.65%
Price Target
$73.53

Earnings Summary

Upcoming
Earnings Date
Oct. 27Estimated
Actual EPS
(Aug. 2)
$1.58 Beat By $0.07
Consensus EPS
(Aug. 2)
$1.51
Last Year's Q3 EPS
(7/29/2021)
$1.87
Skip Charts & View Estimated and Actual Earnings Data

GILD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

GILD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Gilead Sciences Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20224$1.38$1.86$1.73 
Q2 20225$1.48$1.60$1.54 
Q3 20226$1.44$1.69$1.60 
Q4 20226$1.28$1.98$1.43 
FY 202221$5.58$7.13$6.31 
Q1 20233$1.43$1.89$1.64 
Q2 20234$1.48$1.62$1.55 
Q3 20234$1.46$1.75$1.62 
Q4 20234$1.31$1.55$1.44 
FY 202315$5.68$6.81$6.24 
Q1 20241$1.85$1.85$1.85 
Q2 20241$1.71$1.71$1.71 

GILD Earnings Date and Information

Gilead Sciences last released its earnings results on August 2nd, 2022. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.51 by $0.07. The company earned $6.26 billion during the quarter, compared to the consensus estimate of $5.88 billion. Gilead Sciences has generated $3.28 earnings per share over the last year ($3.28 diluted earnings per share) and currently has a price-to-earnings ratio of 19.0. Earnings for Gilead Sciences are expected to decrease by -4.98% in the coming year, from $6.63 to $6.30 per share. Gilead Sciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 27th, 2022 based off prior year's report dates.

Gilead Sciences Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
10/27/2022
(Estimated)
        
8/2/2022Q2 2022$1.51$1.58+$0.07$2.25$5.88 billion$6.26 billion
4/28/2022Q1 2022$1.77$2.12+$0.35$4.22$6.28 billion$6.59 billion      
2/1/2022Q4 2021$1.53$0.69($0.84)$1.08$6.64 billion$7.24 billion    
10/28/20219/30/2021$1.72$2.65+$0.93$3.25$6.31 billion$7.42 billion    
7/29/20216/30/2021$1.76$1.87+$0.11$2.53$6.15 billion$6.22 billion      
4/29/20213/31/2021$2.06$2.08+$0.02$2.79$6.78 billion$6.42 billion  
2/4/202112/31/2020$2.15$2.19+$0.04$3.15$7.11 billion$7.42 billion  
10/28/20209/30/2020$1.90$2.11+$0.21$3.93$6.20 billion$6.58 billion  
7/30/20206/30/2020$1.57$1.11($0.46)$4.88$5.24 billion$5.14 billion  
4/30/20203/31/2020$1.57$1.68+$0.11$2.14$5.44 billion$5.55 billion  
2/4/2020Q4 2019$1.67$1.30($0.37)$0.08$5.74 billion$5.88 billion  
10/24/2019Q3 19$1.74$1.75+$0.01$4.22$5.61 billion$5.60 billion  
7/30/20196/30/2019$1.68$1.82+$0.14$1.97$5.54 billion$5.69 billion  
5/2/20193/31/2019$1.53$1.76+$0.23$1.80$5.29 billion$5.28 billion  
2/4/201912/31/2018$1.70$1.44($0.26)$2.68$5.52 billion$5.80 billion  
10/25/20189/30/2018$1.63$1.84+$0.21$1.80$5.44 billion$5.60 billion  
7/25/2018Q2 2018$1.56$1.91+$0.35$2.11$5.20 billion$5.65 billion
5/1/2018Q1 2018$1.67$1.48($0.19)$1.57$5.40 billion$5.09 billion  
2/6/2018Q4 2017$1.67$1.78+$0.11$6.16$5.71 billion$5.95 billion  
10/26/2017Q3 2017$2.13$2.27+$0.14$2.40$6.40 billion$6.51 billion
7/26/2017Q2 2017$2.11$2.56+$0.45$2.69$6.35 billion$7.14 billion
5/2/2017Q1 2017$2.18$2.20+$0.02$2.35$6.66 billion$6.51 billion  
2/7/2017Q416$2.61$2.70+$0.09$2.94$7.16 billion$7.30 billion  
11/1/2016Q316$2.87$2.75($0.12)$2.91$7.47 billion$7.40 billion  
7/25/2016Q216$3.02$3.08+$0.06$3.48$7.80 billion$7.78 billion  
4/28/2016Q116$3.13$3.03($0.10)$3.43$8.08 billion$7.80 billion  
2/2/2016Q415$3.00$3.32+$0.32$3.36$8.11 billion$8.51 billion  
10/27/2015Q315$2.87$3.22+$0.35$3.32$7.84 billion$8.30 billion  
7/28/2015Q215$2.83$3.15+$0.32$3.28$7.60 billion$8.22 billion  
4/30/2015Q115$2.78$2.94+$0.16$3.02$6.81 billion$7.59 billion  
2/3/2015Q414$2.27$2.43+$0.16$2.58$6.68 million$7.31 billion  
10/28/2014Q314$1.92$1.84($0.08)$1.91$5.99 billion$6.04 billion  
7/23/2014Q214$1.61$2.36+$0.75$2.44$5.68 billion$6.53 billion  
4/22/2014Q114$0.75$1.48+$0.73$1.55$3.80 billion$5.00 billion  
2/4/2014Q4 2013$0.49$0.52+$0.03$0.57$2.85 billion$3.04 billion  
10/29/2013Q3 2013$0.47$0.50+$0.03$0.53$2.72 billion$2.78 billion  
7/25/2013Q2 2013$0.48$0.48$0.50$2.66 billion$2.77 billion  
5/2/2013Q1 2013$0.47$0.45($0.02)$0.47$2.57 billion$2.53 billion  
2/4/2013Q4 2012$0.48$0.50+$0.02$2.43 billion$2.59 billion  
10/23/2012$0.94$1.00+$0.06  
7/26/2012$0.95$0.99+$0.04  
4/26/2012$0.94$0.91($0.03)
2/2/2012$1.04$0.97($0.07)
10/27/2011$1.01$1.02+$0.01
7/26/2011Q2 2011$0.48$0.47($0.01)$0.47
4/20/2011$0.97$0.87($0.10)
1/25/2011$0.95$0.95  
10/19/2010Q3 2010$0.42$0.43+$0.01$0.44
7/20/2010Q2 2010$0.41$0.40($0.01)$0.40
4/20/2010Q1 2010$0.46$0.47+$0.01$0.48
1/26/2010Q4 2009$0.41$0.45+$0.04$0.47
10/20/2009Q3 2009$0.35$0.37+$0.02$0.38
7/21/2009Q2 2009$0.31$0.33+$0.02$0.35
4/21/2009Q1 2009$0.30$0.32+$0.02$0.32
1/27/2009Q4 2008$0.28$0.30+$0.02$0.30
10/16/2008Q3 2008$0.25$0.26+$0.01$0.26
7/17/2008Q2 2008$0.25$0.23($0.02)$0.23
4/16/2008Q1 2008$0.24$0.26+$0.02$0.26
1/23/2008Q4 2007$0.21$0.21$0.21












Gilead Sciences Earnings - Frequently Asked Questions

When is Gilead Sciences's earnings date?

Gilead Sciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 27th, 2022 based off last year's report dates. Learn more on GILD's earnings history.

Did Gilead Sciences beat their earnings estimates last quarter?

In the previous quarter, Gilead Sciences (NASDAQ:GILD) reported $1.58 earnings per share (EPS) to beat the analysts' consensus estimate of $1.51 by $0.07. Learn more on analysts' earnings estimate vs. GILD's actual earnings.

How much revenue does Gilead Sciences generate each year?

Gilead Sciences (NASDAQ:GILD) has a recorded annual revenue of $27.31 billion.

How much profit does Gilead Sciences generate each year?

Gilead Sciences (NASDAQ:GILD) has a recorded net income of $6.23 billion. GILD has generated $3.28 earnings per share over the last four quarters.

What is Gilead Sciences's price-to-earnings ratio?

Gilead Sciences (NASDAQ:GILD) has a trailing price-to-earnings ratio of 19.01 and a forward price-to-earnings ratio of 9.40. The price/earnings-to-growth ratio is 0.61.

What is Gilead Sciences's EPS forecast for next year?

Gilead Sciences's earnings are expected to decrease from $6.63 per share to $6.30 per share in the next year, which is a -4.98% change.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:GILD) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.